Fig. 7From: Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s diseaseSignificant increase in LacCer and GM3 levels, but significant decrease in complex ganglioside levels in CSF of PD patients. Ante-mortem CSF from control subjects (n = 15) and age-matched PD patients (n = 28) was used to determine LacCer (a), GA2 (b), GM3 (c), GM2 (d), GD3 (e), GM1a (f), GD1a (g), GD1b (h), and GT1b (i) levels with NP-HPLC (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, unpaired t-test). j Total ganglioside levels (sum of GM1a, GD1a, GD1b and GT1b) in ante-mortem CSF from control subjects and PD patients (** = p < 0.01, unpaired t-test). Data are presented as mean ± SDBack to article page